Inhaled treprostinil in pulmonary hypertension associated with COPD

As part of its June issue, the European Respiratory Journal presents the latest in its series of podcasts.


Deputy Chief Editor Don Sin interviews Steven D. Nathan (Inova Fairfax Hospital, Falls Church, VA, USA) about the PERFECT study, which showed that inhaled treprostinil does not demonstrate a positive risk-benefit ratio in favour of treatment in pulmonary hypertension associated with COPD.


Download the podcast

Listen on Soundcloud

Listen on Spotify

Listen on Apple Podcasts

Recent episodes

Watch previous episodes

Load more